Homepage > Company > Media > Pharma News > 2021 > Toripalimab FDA Approval Status

Toripalimab FDA Approval Status

Toripalimab is an anti-PD-1 monoclonal antibody in development for the treatment of nasopharyngeal carcinoma.

Toripalimab works to recharge the immune system’s ability to attack and kill tumor cells by blocking PD-1 interactions with the PD-L1 and PD-L2 ligands.

A Biologics License Application (BLA) has been submitted to FDA for toripalimab in combination with gemcitabine and cisplatin for first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and toripalimab monotherapy for second-line or above treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.

The FDA has also granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and orphan drug designation for NPC, mucosal melanoma and soft tissue sarcoma.

Sep 6, 2021

https://www.drugs.com/

Read also

uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate

Agency torpedoes company's plans to submit BLA for gene therapy AMT-130 in Q1 2026.

Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn

Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn.

Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges

Femasys (FEMY) on Monday said that the FDA approved continuation of the final phase of its FemBloc pivotal trial, sending shares 25% higher in premarket trading.

Praxis announces

Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback